Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
2000 1
2001 1
2003 3
2005 1
2006 1
2007 3
2008 2
2009 3
2010 5
2011 2
2012 6
2013 5
2014 5
2015 2
2016 3
2017 6
2018 4
2019 5
2020 16
2021 10
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

82 results
Results by year
Filters applied: . Clear all
Page 1
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.
Limagne E, Nuttin L, Thibaudin M, Jacquin E, Aucagne R, Bon M, Revy S, Barnestein R, Ballot E, Truntzer C, Derangère V, Fumet JD, Latour C, Rébé C, Bellaye PS, Kaderbhaï CG, Spill A, Collin B, Callanan MB, Lagrange A, Favier L, Coudert B, Arnould L, Ladoire S, Routy B, Joubert P, Ghiringhelli F. Limagne E, et al. Among authors: favier l. Cancer Cell. 2022 Feb 14;40(2):136-152.e12. doi: 10.1016/j.ccell.2021.12.009. Epub 2022 Jan 19. Cancer Cell. 2022. PMID: 35051357
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.
Mazieres J, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti GR, Tiffon C, Mahier-Ait Oukhatar C, Blay JY. Mazieres J, et al. Among authors: favier l. Ann Oncol. 2020 Feb;31(2):289-294. doi: 10.1016/j.annonc.2019.10.022. Epub 2020 Jan 3. Ann Oncol. 2020. PMID: 31959346 Free article.
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F; MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Pignata S, et al. Among authors: favier l. Lancet Oncol. 2021 Feb;22(2):267-276. doi: 10.1016/S1470-2045(20)30637-9. Lancet Oncol. 2021. PMID: 33539744 Clinical Trial.
Mevalonate kinase deficiency: current perspectives.
Favier LA, Schulert GS. Favier LA, et al. Appl Clin Genet. 2016 Jul 20;9:101-10. doi: 10.2147/TACG.S93933. eCollection 2016. Appl Clin Genet. 2016. PMID: 27499643 Free PMC article. Review.
[Angiogenesis targeting in breast cancer].
Fumoleau P, Coudert B, Mayer F, Isambert N, Favier L, Ferrant E. Fumoleau P, et al. Among authors: favier l. Bull Cancer. 2007;94(7 Suppl):F199-206. Bull Cancer. 2007. PMID: 17964997 Review. French.
Low Cross-Reactivity Between Cisplatin and Other Platinum Salts.
Pasteur J, Favier L, Pernot C, Guerriaud M, Bernigaud C, Lepage C, Jouve JL, Isambert N, Collet E. Pasteur J, et al. Among authors: favier l. J Allergy Clin Immunol Pract. 2019 Jul-Aug;7(6):1894-1900. doi: 10.1016/j.jaip.2019.01.057. Epub 2019 Feb 15. J Allergy Clin Immunol Pract. 2019. PMID: 30776524
82 results